7 registrations that name diosmin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 7 registrations
Status
Phase
All 7 registrations
RecruitingNCT06584799
Venoactive Drug Treatment of Pelvic Venous Disorders
Phase 3
Pirogov Russian National Research Medical University
About 150 people
Starts Dec 2024 (estimated)
In plain words A Phase 3 study of diosmin in female participants 18 to 45, run by Pirogov Russian National Research Medical University. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 45. Conditions: Pelvic Venous Disorders.
Age from 18 to 45 years;
The presence of PeVD symptoms (CPP, dyspareunia, discomfort in the hypogastrium, dysuria, vulvar varicose veins);
The presence of pelvic varicose veins with reflux in them, according to DUS;
Pelvic venous reflux (PVR) lasting for greater than 1 s, according to DUS;
2 more inclusion criteria and the exclusion criteria are on the listing.
Venoactive drug (VAD) therapy is one of the most effective methods of treating chronic venous diseases (CVD). Numerous studies have proven its high efficacy in relieving symptoms of CVD, such as leg pain and swelling, leg heaviness and fatigue. Pelvic venous disorders (PeVDs) represent a group of pathological conditions including varicose veins of the pelvis and vulva, and compression stenoses of the left renal and common iliac veins. The full summary is on the listing.
Where, as registered
No US site; Russia (1).
RecruitingNCT07598214
Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients
Phase 4
Beni-Suef University
About 100 people
Started Feb 3, 2025
In plain words A Phase 4 study of diosmin in people 18 to 75, run by Beni-Suef University. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Cancer Patients.
Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.
The exclusion criteria are on the listing.
What it tests, as registered
diosmin/hesperdin
Registered summary
The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07293767
Silymarin vs Hesperidin/Diosmin in Fibromyalgia
No phase
Ain Shams University
About 90 people
Started Nov 16, 2024
In plain words A study of diosmin in people 18 to 60, run by Ain Shams University. It plans to enroll about 90 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Fibromyalgia (FM).
Informed written consent.
Participant must meet the American College of Rheumatology 2016 revised classification criteria for Fibromyalgia: Widespread pain index (WPI) ≥ 7 and symptom severity (SS) scale score ≥ 5, or WPI 3 to 6 and SS scale score ≥ 9
Age >18 years old (males and females)
Diagnosis of FM confirmed by a rheumatologist.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Silymarin (LEGALON); Diosmin / Hesperidin (Daflon); no intervention (control group)
Registered summary
Fibromyalgia is a chronic disease, characterized by chronic widespread pain, physical exhaustion, sleep problems, and unexplained pain in both joints and muscles. Fibromyalgia's causes still unknown, but there are various risk factors that can cause fibromyalgia such as genetic causes, physical shock, and infections. Fibromyalgia typically presents in young or middle aged females, it occurs in females more than males, and it is characterized with widespread pain throughout the whole body in both sides such as arms, shoulders, head, and abdominal areas. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
RecruitingNCT07300735
Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers
No phase
Alexandria University
About 88 people
Started Mar 1, 2025
In plain words A study of diosmin in people 18 to 65, run by Alexandria University. It plans to enroll about 88 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Hematologic Malignancy; Neutropenia; Bone Pain.
Adults 18 to 65 years old
Receiving a G-CSF for one of the following indications:
Patients with or without bone pain associated with G-CSF administration.
Willingness to provide informed consent to participate in the study.
This is a comparative interventional study to determine the best way to prevent G-CSF induced bone pain in patients with hematological malignancies (blood cancers). G-CSF (Granulocyte Colony-Stimulating Factor) is a drug commonly used in these patients to boost white blood cell production, but it frequently causes severe bone pain. The study is comparing two oral medications for their effectiveness as a preventive treatment: * Diosmin-Hesperidin (a flavonoid supplement). * Loratadine (a common anti-allergy medication). The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
RecruitingNCT05756179
Effect of Diosmin and Hesperidin in Treatment of Patients With Rheumatoid Arthritis
Phase 3
Alexandria University
About 80 people
Started Jul 18, 2023
In plain words A Phase 3 study of diosmin in people 19 to 65, run by Alexandria University. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 19 to 65. Conditions: Rheumatoid Arthritis.
Patients with mild to moderate disease activity.
Patient age must be more than 18 years.
The exclusion criteria are on the listing.
What it tests, as registered
Diosmin and Hesperidin Combination
Registered summary
Evaluating the effect of the flavonoids combination (diosmin and hesperidin) as adjuvant therapy on patients with rheumatoid arthritis
Where, as registered
No US site; Egypt (1).
RecruitingNCT07745426
Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis
Phase 2
Tanta University
About 66 people
Starts Aug 1, 2026 (estimated)
In plain words A Phase 2 study of diosmin in people 18 to 70, run by Tanta University. It plans to enroll about 66 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Rheumatoid Arthritis (RA).
Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR). i.e.,28 joints disease activity score (DAS-28) >2.6.
Both sexes.
Age ranges between 18 and 70 years old.
Patients receiving conventional DMARDs
The exclusion criteria are on the listing.
What it tests, as registered
Diosmin; Rebamipide 100mg; Convential medical treatment
Registered summary
This study will be a randomized controlled parallel study that will be conducted on 66 patients with active rheumatoid arthritis who will be diagnosed with RA according to American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR, 2010). The patients will be recruited from Outpatient Clinic of Rheumatology, Physical Medicine, Rheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt. The study duration will be 3 months. The full summary is on the listing.
Where, as registered
No US site; Egypt (1).
RecruitingNCT06256575
Study of Diosmin for the Treatment of Digital Ulcers in Systemic Sclerosis
No phase
Primus Pharmaceuticals
About 45 people
Started May 2, 2025
In plain words A study of diosmin in people 18 and older, run by Primus Pharmaceuticals. It plans to enroll about 45 people at 5 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Scleroderma, Systemic; Digital Ulcer.
Diagnosis of systemic sclerosis (scleroderma)
At least one "active" digital ulcer
Medication for systemic sclerosis unchanged for 30 days
The exclusion criteria are on the listing.
What it tests, as registered
Diosmin; Placebo
Registered summary
This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). Two (2) out of three (3) participants will receive active product. The participants will have four (4) visits over eight (8) weeks. Physical exams and photos will be performed. A variety of questions will be asked describing level of pain and lifestyle changes.